Jack Ma Moved A Step Further Into Pharmaceutical Industry
2015/1/18 E药经理人

     On January 12th, GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLIDNGS CO., LTD, the well-known listed subsidiary of Guangzhou Pharmaceutical Holdings Limited, announced its private placement plan. When this plan showed up in the market, great attention came along. In the day after, BAIYUNSHAN PHARMACEUTICAL 's price climbed 10% in China's mainland A stock market and hit its daily limit. In Hong Kong stock market, its stock price rose by 18.8%.

     The private placement is worth 10 billion yuan, which set the new record in China's mainland A stock market. Besides its being the largest private placement, what fueled up the heat is there is an investment management company on the buyer list. This company is willing to pay 500 million yuan. What's so special about it? Nothing about the company itself is special but Jack Ma is on its board as one of its stock holder. It is believed that Ma moved a step further into China's pharmaceutical industry by this purchase. The first real move Jack Ma made was investing 170 million yuan also through the same company into CITIC 21CN, a Hong Kong listed telecommunication company, and became its controlling shareholder. CITIC 21CN now is called Alibaba Health Information Technology Limited and its expertise is PIATS service.

     The scale of the stock options given to the group's staff can be described as pioneering and bold.

    

    

    http://www.duyihua.cn
返回 E药经理人 返回首页 返回百拇医药